Established in 1969, Plastiape is a leading Italian based manufacturer of medical devices and pharma primary packaging. The company produces a number of pharma solutions at three sites: Osnago and Sirone in Italy and Garwolin in Poland. Plastiape has a turnover of approximately £43m in yearly sales.
Plastiape's acquisition will place it in the RPC Bramlage Division. The move is part of the RPC Group's strategy to build and enhance a growth platform in the health care sector. RPC's Bramlage Division therefore expands from five to six sub-divisions. The new RPC Pharma Cluster is consequently established with this new acquisition. Plastiape reinforces RPC's leading position in the health care and pharmaceutical sectors, providing the group with additional qualified resources and manufacturing capabilities.
Established in the UK in 1991, RPC is a global design and engineering company specializing in polymer conversion in the packaging and non-packaging markets, with centres of excellence worldwide. The group currently depends upon 150 operations in 30 countries with a yearly turnover in excess of £2bn.
According to Gianluca Baccheschi, Plastiape's Marketing Director:
"We are very excited to become part of RPC. We have the opportunity to combine Plastiape's numerous years of expertise and unparalleled products with RPC’s expansive global footprint and excellence in product development and manufacturing capabilities. Customers will benefit greatly from the expanded product portfolio as well as the combined design and manufacturing capabilities. We will remain fully focused on our customers and build on our increased offering to deliver even greater value."